Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EQRx Starts US Phase III Trial of Hansoh’s EGFR for NSCLC

publication date: Aug 12, 2022

Boston’s EQRx has started a US Phase III trial of its in-licensed EGFR therapy in patients with lung cancer. EQRx acquires drugs developed in China, which it plans to offer in western markets at substantially lower prices than existing products. In 2021, the company acquired western rights to aumolertinib from Hansoh for a $100 million upfront payment, plus milestones and royalties. The new US trial will be a bridging test to see if US patients experience the same results as patients in Hansoh’s China trial. Earlier this year, the US FDA declined to approve an Innovent/Lilly PD-1 based only on China data. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital